BIOLASE PLANS TO LAUNCH SEASON 2 OF ITS POPULAR PODCAST SERIES

News provided by

Mar 06, 2023, 06:30 ET

New Episodes Will Feature Engaging Stories from Clinicians About the Benefits of Laser Technology in Dentistry

LAKE FOREST, Calif., March 6, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced plans to launch a second season of the popular podcast series, "BIOLASE: Advancing Dentistry." Due to the overwhelmingly positive response from the dental community, the rising interest and popular demand, the second season will maintain the high level of excellence associated with the BIOLASE podcast. Season 2 will continue to provide world-class education in a readily accessible and visually appealing format focusing on trending topics for dental clinicians, including how the Company's Waterlase technology can improve patient and practice outcomes. The podcast will continue to be available on Spotify and Apple podcast platforms.

Dr. Stephen John, DDS, a periodontist with over 17 years of Waterlase experience, will return to host season 2. Dr. John's extensive experience and connections within the dental community have allowed BIOLASE access to the top echelon of practitioners in the industry, and listeners will continue to be able to tune into these conversations in season 2 of the podcast.

"The BIOLASE Advancing Dentistry podcast has been a rewarding, entertaining, and value-added resource for our BIOLASE education community," commented John Beaver, President and Chief Executive Officer of BIOLASE. "We are committed to raising the awareness of our Waterlase technology, and this focused educational offering exemplifies our industry leadership and commitment to educating patients and clinicians and making laser dentistry the gold standard of care."

Past episodes have included a three-part peri-implantitis management series with key opinion leaders (KOLs), including Dr. Samuel Low's two-part discussion with Dr. Howard Golan, which focused on restorative and soft tissue surgeries for the general dentist using Waterlase. Additionally, season 1 also included a three-part exploration of the game-changing implementation of Epic diode lasers for the hygiene practice with Lynn Atkinson, a pioneering hygiene educator. Other guests have included Dr. Ben Curtis, who focused on Waterlase benefits to pediatrics, Dr. Scott Thompson's discussion on BIOALSE's unique Waterlase Exclusive Trial Program, and additional podcasts with Dr. Low, which centered on the release of new minimally-invasive esthetic protocols.

Season 2 episodes will feature Dr. Stephen John and distinguished guests, including notable peri-implantitis expert Dr. Paul Chang, a dual board certified periodontist and prosthodontist; laser integration and return on investment (ROI) expert Dr. Russell Morrow; the former Regional Doctor Mentor of Operations for Heartland Dental DSO, Dr. Rishita Jaju, a Harvard-trained pediatric dentist with an Advanced Laser Proficiency certification; and other guests discussing trending topics, including holistic dentistry.

All episodes are available at the following links: Spotify, Apple and BIOLASE Podcasts.

About BIOLASE

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE's proprietary laser products incorporate approximately 302 patented and 28 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. From 1998 through December 31, 2021, BIOLASE has sold over 43,300 laser systems in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.

BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements, regarding BIOLASE's expected revenue and revenue growth and beliefs regarding its financial resources. Forward-looking statements can be identified through the use of words such as "may," "might," "will," "intend," "should," "could," "can," "would," "continue," "expect," "believe," "anticipate," "estimate," "predict," "outlook," "potential," "plan," "seek," and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors. These factors include, among others, the coronavirus (COVID-19) and the effects of the outbreak and actions taken in connection therewith, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that are described in the "Risk Factors" section of BIOLASE's most recent annual report filed on Form 10-K filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.

For further information, please contact:

EVC Group LLC
Michael Polyviou / Todd Kehrli
(732) 933-2754
[email protected] / [email protected]

SOURCE BIOLASE, Inc.